Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$132.63 -0.4%	$126.65	$110.04 ▼ $238.00	$19.52B	0.14	1.43 million shs	633,328 shs
BMRN BioMarin Pharmaceutical	$57.25 +0.1%	$58.00	$52.93 ▼ $94.85	$10.96B	0.17	1.73 million shs	1.38 million shs
INCY Incyte	$68.46 +0.4%	$65.34	$53.56 ▼ $83.95	$13.20B	0.68	1.97 million shs	1.27 million shs
UTHR United Therapeutics	$294.57 -0.2%	$301.15	$266.98 ▼ $417.82	$13.32B	0.53	445,700 shs	284,212 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	-0.42%	+4.49%	+0.60%	+7.84%	-40.95%
BMRN BioMarin Pharmaceutical	+0.14%	+5.82%	+0.81%	-5.00%	-29.30%
INCY Incyte	+0.43%	-3.32%	+2.01%	+13.01%	+18.73%
UTHR United Therapeutics	-0.22%	+3.69%	-9.14%	+0.72%	-5.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.943 of 5 stars	4.2	5.0	3.7	3.8	1.7	1.9
BMRN BioMarin Pharmaceutical	4.9422 of 5 stars	3.4	3.0	3.3	2.8	2.5	4.4
INCY Incyte	4.3982 of 5 stars	2.1	3.0	3.1	2.5	2.5	3.1
UTHR United Therapeutics	4.9955 of 5 stars	4.3	5.0	4.6	3.5	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.38	Hold	$188.48	42.12% Upside
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$93.61	63.51% Upside
INCY Incyte	2.22	Hold	$74.53	8.87% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$386.15	31.09% Upside

Current Analyst Ratings Breakdown

Latest BMRN, BIIB, INCY, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$97.00
6/30/2025	UTHR United Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$410.00 ➝ $385.00
6/26/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$187.00
6/25/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$205.00 ➝ $213.00
6/23/2025	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$67.00
6/16/2025	INCY Incyte	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00 ➝ $107.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/11/2025	UTHR United Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$321.00 ➝ $315.00
6/3/2025	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.01	$23.03 per share	5.76	$114.71 per share	1.16
BMRN BioMarin Pharmaceutical	$2.85B	3.85	$3.25 per share	17.61	$29.69 per share	1.93
INCY Incyte	$4.24B	3.12	$0.56 per share	123.14	$17.90 per share	3.82
UTHR United Therapeutics	$2.88B	4.62	$28.32 per share	10.40	$144.34 per share	2.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	13.09	8.03	1.06	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$426.86M	$2.69	21.28	13.13	0.78	17.76%	11.34%	8.95%	8/4/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	213.94	10.47	0.57	0.48%	2.77%	1.77%	7/29/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.06	11.75	10.72	6.46	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest BMRN, BIIB, INCY, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.89	N/A	N/A	N/A	$802.13 million	N/A
7/29/2025	Q2 2025	INCY Incyte	$1.38	N/A	N/A	N/A	$1.15 billion	N/A
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.44	1.01
BMRN BioMarin Pharmaceutical	0.10	5.52	3.49
INCY Incyte	0.01	2.04	2.00
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
BMRN BioMarin Pharmaceutical	98.71%
INCY Incyte	96.97%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.18%
BMRN BioMarin Pharmaceutical	0.85%
INCY Incyte	17.80%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
BMRN BioMarin Pharmaceutical	3,040	191.78 million	190.15 million	Optionable
INCY Incyte	2,617	193.57 million	159.12 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

BMRN, BIIB, INCY, and UTHR Headlines

Recent News About These Companies

New York State Teachers Retirement System Lowers Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

July 3 at 4:34 AM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Holdings Raised by Sumitomo Mitsui Trust Group Inc.

July 3 at 4:24 AM | marketbeat.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

July 2 at 9:56 AM | zacks.com

Amalgamated Bank Trims Position in United Therapeutics Corporation (NASDAQ:UTHR)

July 2 at 5:16 AM | marketbeat.com

Allspring Global Investments Holdings LLC Decreases Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

July 2 at 4:31 AM | marketbeat.com

Wealth Enhancement Advisory Services LLC Sells 2,214 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 2 at 3:16 AM | marketbeat.com

Diversified Trust Co Purchases 1,074 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 1 at 4:26 AM | marketbeat.com

Bessemer Group Inc. Cuts Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

July 1 at 3:56 AM | marketbeat.com

Cambridge Investment Research Advisors Inc. Purchases 2,211 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 1 at 3:37 AM | marketbeat.com

UBS Group Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $385.00

June 30, 2025 | marketbeat.com

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment

June 30, 2025 | tipranks.com

KBC Group NV Has $33.63 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

June 30, 2025 | marketbeat.com

Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock

June 29, 2025 | americanbankingnews.com

United Therapeutics Corporation (UTHR) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 Shares

June 28, 2025 | insidertrades.com

United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study

June 28, 2025 | msn.com

UTHR United Therapeutics Corporation - Seeking Alpha

June 27, 2025 | seekingalpha.com

Insider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock

June 27, 2025 | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Achmea Investment Management B.V.

June 27, 2025 | marketbeat.com

Robeco Institutional Asset Management B.V. Buys 34,362 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

June 27, 2025 | marketbeat.com

Contrasting United Therapeutics (NASDAQ:UTHR) and Journey Medical (NASDAQ:DERM)

June 27, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN, BIIB, INCY, and UTHR Company Descriptions

Biogen NASDAQ:BIIB

$132.62 -0.57 (-0.42%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$132.87 +0.25 (+0.18%)

As of 07/3/2025 04:57 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$57.25 +0.08 (+0.14%)

Closing price 07/3/2025 03:45 PM Eastern

Extended Trading

$57.24 -0.01 (-0.01%)

As of 07/3/2025 04:58 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Incyte NASDAQ:INCY

$68.46 +0.29 (+0.43%)

Closing price 07/3/2025 03:25 PM Eastern

Extended Trading

$67.23 -1.23 (-1.80%)

As of 07/3/2025 04:18 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

United Therapeutics NASDAQ:UTHR

$294.57 -0.65 (-0.22%)

Closing price 07/3/2025 02:47 PM Eastern

Extended Trading

$294.57 0.00 (0.00%)

As of 07/3/2025 04:32 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time